Terran Biosciences is developing a portfolio of drugs, an imaging device, and a precision medicine platform to treat a variety of neurological and psychiatric illnesses.
Terran Biosciences
Their drug candidate TR-01 is in phase II clinical trials and targets schizophrenia. And TR-36 is in phase I of the clinical trial process and is targeting depression and schizophrenia.
Activities
B2B
Biotech
Drug Discovery
Topics of Interest
Technology
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates